Syndax Pharmaceuticals Inc
SNDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001395937
In the last 90 days, Syndax Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 242 institutions reported holding it in 13F filings for Q2 2026, worth $2.36B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Syndax Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $784.8K in total
- Insiders trading
- 1
- Net value
- −$784.8K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Syndax Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer | 484,843 | Jul 9, 2026 | 4 |
| Botwood Nicholas A.J. | Head of R&D, CMO | 60,885 | Jun 12, 2026 | 2 |
| Goldan Keith A. | Chief Financial Officer | 139,252 | Jun 2, 2026 | 4 |
| Podlesak Dennis | Director | 239,763 | Feb 6, 2026 | 1 |
| Katkin Keith | Director | 124,000 | Feb 6, 2026 | 1 |
| Legault Pierre | Director | 114,000 | Feb 6, 2026 | 1 |
| Huber Martin H. Jr. | Director | 103,000 | Feb 6, 2026 | 1 |
| Jarrett Jennifer | Director | 114,000 | Feb 6, 2026 | 1 |
| Rizo Aleksandra | Director | 49,000 | Feb 6, 2026 | 1 |
| Gallagher Neil | President, Head of R&D | 85,095 | Feb 12, 2025 | 0 |
| Meury William | Director | 90,000 | Feb 7, 2025 | 0 |
| Morrison Briggs | Director | 34,836 | Feb 9, 2024 | 0 |
| Ordentlich Peter | Chief Scientific Officer | 0 | Feb 17, 2023 | 0 |
| Nolte Alexander | Chief Accounting Officer | 0 | Feb 3, 2023 | 0 |
| Madigan Catherine | Chief Medical Officer | – | Feb 3, 2023 | 0 |
| Sabus Steve M | Chief Commercial Officer | – | Dec 5, 2022 | 0 |
| Egros Fabrice | Director | 32,000 | Feb 3, 2022 | 0 |
| Meyers Michael L. | SVP, Chief Medical Officer | 23,280 | Feb 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 22, 2021 (view filing) | Dec 20-22 | 2 days | Legault PierreDirector | SSale | −44.0K | $21.56 | −$948.4K | −73.3%16.0K after | 2 lots |
| Dec 20, 2021 (view filing) | Dec 17 | 3 days | Morrison BriggsChief Executive Officer | SSale | −35.2K | $20.00 | −$703.1K | −42.1%48.3K after | |
| Dec 20, 2021 (view filing) | Dec 16-20 | 4 days | Metzger Michael APresident and COO | SSale | −85.4K | $19.94 | −$1.70M | −82.9%17.7K after | 4 lots |
| Dec 15, 2021 (view filing) | Dec 13 | 2 days | Metzger Michael APresident and COO | SSale | −36.6K | $19.05 | −$697.4K | −67.5%17.7K after | 2 lots |
| Nov 19, 2021 (view filing) | Nov 18 | 1 day | Egros FabriceDirector | SSale | −14.0K | $18.03 | −$253.0K | −46.7%16.0K after | 2 lots |
| Oct 27, 2021 (view filing) | Oct 25-26 | 2 days | Metzger Michael APresident and COO | SSale | −61.0K | $19.15 | −$1.17M | −77.5%17.7K after | 2 lots |
| Sep 28, 2021 (view filing) | Sep 27 | 1 day | Metzger Michael APresident and COO | SSale | −24.4K | $19.51 | −$476.8K | −58.1%17.7K after | |
| Sep 22, 2021 (view filing) | Sep 20-22 | 2 days | Metzger Michael APresident and COO | SSale | −36.6K | $19.23 | −$703.0K | −67.4%17.7K after | 3 lots |
| Sep 21, 2021 (view filing) | Sep 17-20 | 4 days | Morrison BriggsChief Executive Officer | SSale | −70.3K | $20.07 | −$1.41M | −59.3%48.3K after | 2 lots |
| Sep 15, 2021 (view filing) | Sep 13-14 | 2 days | Metzger Michael APresident and COO | SSale | −61.0K | $19.11 | −$1.17M | −77.5%17.7K after | 2 lots |
| Aug 20, 2021 (view filing) | Aug 18 | 2 days | Egros FabriceDirector | SSale | −15.6K | $15.75 | −$246.3K | −49.4%16.0K after |